Lilly banishes baricitinib blues with strong 1st-qtr results

24 April 2018

The week started badly for Eli Lilly (NYSE: LLY) with a potential setback in its hopes to gain US approval for baricitinib in rheumatoid arthritis, but things took a turn for the better on Tuesday with the presentation of the company’s financial results for the first quarter of 2018.

Earnings and revenue for the quarter beat the expectations of analysts and Lilly has also raised its 2018 earnings per share (EPS) estimate to a range of $5.10 to $5.20 from the previous $4.81 to $4.91, and its sales prediction to $23.7 billion to $24.2 billion from $23 billion to $23.5 billion.

'New growth era'

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK